Aclarion, Inc., a commercial-stage healthcare technology company, announced its participation in the 38th Annual ROTH Conference scheduled for March 22-24, 2026, in Dana Point, California. The company, which trades on Nasdaq under the symbols ACON and ACONW, focuses on leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying the location of chronic low back pain.
During the conference, CEO Brent Ness will conduct one-on-one meetings with institutional investors and analysts to outline the company's progress with Nociscan, its proprietary magnetic resonance spectroscopy platform. Nociscan is designed as a SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology receives MRS data from MRI machines via a cloud connection, where proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain. This data is then analyzed by AI algorithms to indicate whether a disc may be a source of pain, providing physicians with critical insights to optimize treatment strategies when used alongside other diagnostic tools.
Ness emphasized the company's strategic position, stating, "We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion. With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead." This statement underscores the company's financial stability and its plans to broaden the reach of its technology in key markets.
The announcement highlights several forward-looking statements regarding the company's expectations, including the enrollment of patients in ongoing clinical trials and potential benefits of the Nociscan technology. These statements are subject to risks and uncertainties, as detailed in the company's filings with the Securities and Exchange Commission, such as the Annual Report on Form 10-K for the year ended December 31, 2024. For more information on Aclarion, visit https://www.aclarion.com.
The implications of this news are significant for the healthcare industry and patients suffering from chronic low back pain, a condition that affects millions worldwide and often leads to costly and invasive treatments. By providing a noninvasive method to pinpoint pain sources, Nociscan could reduce unnecessary surgeries and improve patient outcomes, potentially lowering healthcare costs. For investors, Aclarion's participation in the ROTH Conference signals confidence in its growth trajectory, supported by a debt-free balance sheet and clear expansion goals. The company's focus on evidence-supported technology positions it to capitalize on the growing demand for precision medicine in orthopedics, making this development noteworthy for stakeholders in medical technology and investment circles.
